Segment 4- Nonadherence Caused by a Lack of Access

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed. “It’s certainly happening for ipilimumab,” said Dr Ribas. “In places like the county hospital it’s hard to find any patient who has been on ipilimumab because it’s not being approved for administration even though it’s an FDA-approved drug and even though there are 2 randomized trials that demonstrated improvement in survival.”